By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Basilea Pharmaceutica 

Grenzacherstrasse 487

Basel    CH-4005  Switzerland
Phone: 41-61-6061-111 Fax: 41-61-6061-112


SEARCH JOBS

Basilea Pharmaceutica is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

YEAR FOUNDED:

October 17, 2000

LEADERSHIP:

Founder: Jan G. J. van de Winkel, Ph.D.

CEO: Ronald Scott

CMO (Medical): Achim Kaufhold

CTO: G√ľnter Ditzinger

CFO: Donato Spota

CSO (Scientific): Laurenz Kellenberger

JOBS:

Please click here for.

CLINICAL TRIAL

Please click here for clinical trial information.


PRODUCTS:

All Products


Key Statistics


Email:
Ownership: Public

Web Site: Basilea
Employees:
Symbol: BSLN.SW
 









Company News
Basilea (BSLN.SW) Forges $491 Million+ Antifungal Deal With Drug Giant Pfizer (PFE) 6/14/2017 11:31:28 AM
Avir Pharma Announces Distribution Agreement With Basilea (BSLN.SW) For Cresemba (Isavuconazole) And Zevtera (Ceftobiprole) In Canada 6/14/2017 7:32:46 AM
Basilea (BSLN.SW) Announces Clinical Study Agreement With Adult Brain Tumor Consortium To Explore BAL101553 In Newly Diagnosed Glioblastoma 6/12/2017 12:07:39 PM
Basilea (BSLN.SW) Announces Presentation Of Interim Phase I/IIa Clinical Data With Anticancer Drug Candidate BAL101553 At ASCO Meeting 6/6/2017 8:22:55 AM
Basilea (BSLN.SW) Names New Member Of Its Extended Management Committee 6/2/2017 9:40:08 AM
Basilea (BSLN.SW) Announces Agreement With FDA On Special Protocol Assessments For Antibiotic Ceftobiprole Phase III Clinical Studies In Bloodstream And Skin Infections 4/21/2017 8:26:56 AM
Basilea (BSLN.SW) Ends Further Development of Inhaled Antibiotic BAL30072 8/15/2016 10:46:19 AM
Clinigen Announces Partnership With Basilea (BSLN.SW) To Initiate A Managed Access Program For Isavuconazole To Treat Patients With Invasive Fungal Infections In Europe 6/9/2016 12:46:27 PM
Basilea (BSLN.SW) Shareholders Approve All Resolutions Proposed By The Board Of Directors At The Ordinary General Meeting Of Shareholders 4/21/2016 10:49:27 AM
Basilea (BSLN.SW) Wins $100 Million Contract to Fund Phase III Ceftobiprole Program 4/20/2016 6:49:47 AM
12345678910...
//-->